Schuette W - Search Results

1

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.

Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Blackhall F, et al. Among authors: schuette w. J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16. J Thorac Oncol. 2021. PMID: 33607312 Free article. Clinical Trial.

2

Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.

Okamoto I, Schuette WH, Stinchcombe TE, Rodrigues-Pereira J, San Antonio B, Chen J, Liu J, John WJ, Zinner RG. Okamoto I, et al. Among authors: schuette wh. Curr Med Res Opin. 2017 May;33(5):937-941. doi: 10.1080/03007995.2017.1297701. Epub 2017 Mar 12. Curr Med Res Opin. 2017. PMID: 28277871

3

Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.

Schuette W, Krzakowski MJ, Massuti B, Otterson GA, Lizambri R, Wei H, Berger DP, Chen Y. Schuette W, et al. J Thorac Oncol. 2012 Jan;7(1):157-64. doi: 10.1097/JTO.0b013e31822f6526. J Thorac Oncol. 2012. PMID: 22011667 Free PMC article. Clinical Trial.

4

Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.

Schuette W, Nagel S, von Weikersthal LF, Pabst S, Schumann C, Deuss B, Salm T, Roscher K, Dickgreber N. Schuette W, et al. J Thorac Oncol. 2011 Dec;6(12):2090-6. doi: 10.1097/JTO.0b013e3182307e3c. J Thorac Oncol. 2011. PMID: 22052225 Free article. Clinical Trial.

5

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M. Schuette WH, et al. Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332288 Clinical Trial.

6

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Taylor P, et al. Among authors: schuette w. J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec. J Thorac Oncol. 2008. PMID: 18594323 Free article.

7

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. Schuette W, et al. J Clin Oncol. 2005 Nov 20;23(33):8389-95. doi: 10.1200/JCO.2005.02.3739. J Clin Oncol. 2005. PMID: 16293869 Clinical Trial.

8

Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.

Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T, Ukena D. Schuette W, et al. Clin Lung Cancer. 2006 Mar;7(5):338-43. doi: 10.3816/clc.2006.n.016. Clin Lung Cancer. 2006. PMID: 16640806 Clinical Trial.

9

Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.

Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W. Nagel S, et al. Among authors: schuette w. Clin Lung Cancer. 2011 Jan;12(1):62-9. doi: 10.3816/CLC.2011.n.009. Clin Lung Cancer. 2011. PMID: 21273182 Clinical Trial.

10

Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.

Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S, Blankenburg T. Schuette W, et al. Clin Lung Cancer. 2005 Sep;7(2):133-7. doi: 10.3816/CLC.2005.n.029. Clin Lung Cancer. 2005. PMID: 16179101 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page